



Dear Chair and members of Economic Matters Committee:

My name is Rama Modali, and I serve as CEO of REPROCELL USA in Beltsville, Maryland. I'm writing to strongly urge you to authorize the Maryland Stem Cell Research Commission, through MSCRF, to operate the regenerative medicine advanced manufacturing grant program under SB0905.

REPROCELL has directly benefited from MSCRF's manufacturing grant program. That support played a key role in our transition from a research-focused company to a GMP manufacturing operation. With MSCRF's help, we were able to build out critical infrastructure, including advanced isolator systems for Master Cell Bank production and a GMP-compliant cleanroom. These investments now allow us to support both research and clinical-stage cell therapy manufacturing as a result, we've been able to grow commercially developing cost-effective research-use products for cell therapy companies, while positioning ourselves to support their transition into clinical manufacturing as they scale.

MSCRF also stands out for how thoughtfully it invests. Their review process is rigorous and focused on projects that have real scientific and commercial potential. We've seen the impact firsthand: MSCRF support has contributed to our revenue growth, with more than 80% of that revenue coming into Maryland from national and international customers. It has also allowed us to hire locally, including graduates from the University of Maryland, and we expect to continue growing our team this year.

Just as important as the funding is the partnership. The MSCRF team understands this field deeply and has been a valuable connector for us. Through their network, we've been able to collaborate with academic scientists, expand our customer base, and build relationships that we likely wouldn't have made otherwise. MSCRF plays a unique role in bringing together industry, academia, and the state to move this field forward. That's not easy to replicate—and it's a big part of why Maryland continues to stand out in regenerative medicine.

For all these reasons, I strongly encourage you to support authorizing MSCRF to lead this program and to continue investing in a model that is clearly working. Thank you for your consideration.

Respectfully,
Rama Modali

Rama Modali, CEO,
REPROCELL, USA
9000 Virginia Manor Rd., Suite 20
Beltsville, MD 20705